Lupin share news and announcements
NSE: LUPINBSE: 500257Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,928.90up ₹6.90 (0.36%)BSE ₹1,925.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,922.00.
52-week range of traded prices to 23 Oct 2026
₹1,892.90Low, 23 Oct 2026₹2,529.50High, 16 Jul 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹88,207 Cr105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 6 Aug 2026
- 16.0
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 14.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 7 May 2026
- 3.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.93%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 6 Aug 2026
- 27.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹558 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 30.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 6 Aug 2026
- 28.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 7 May 2026
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,02,15655.7% delivered
Lupin share news and announcements
2,116 announcements, routine notices left out, newest first. Page 43 of 43.
Mar 2007
28 Mar · Disclosure
Mr. Alok Kumar Ghosh, Officer of the company holds Nil Equity shares of Lupin Limited as on date of joining i.e. March 23, 2007.21 Mar · E-mail ID for Investor Complaints
We have designated following email - ID exclusively for redressal of investor complaints: [email protected]. We would like to add the above email-ID has been linked through our website - www.lupinworld.com13 Mar · Business
Press release dated March 13, 2007, titled "Lupin gets Marketing Approval for Cefpodoxime Proxetil in France". The copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Mar · Disclosure
Dr. K H Sreedhara Swamy, Officer of the company holds Nil Equity shares of Lupin Limited as on date of joining i.e. on March 07, 20076 Mar · Disclosure
Mr. Jaideep Bhaduri, Officer of the company holds Nil shares of Lupin Limited as on date of joining i.e. on March 02, 20071 Mar · Demise of Director
Mr. P.K. Kaul, a Director of the Company expired on February 28, 2007
Feb 2007
20 Feb · Business
An Agreement entered into by the Company for the sale of certain patent applications and related intellectual Property for Perindopril to Laboratories Servier of France. A copy of press release in this regard titled "Lupin sells Intellectual Property on Perindopril to Servier" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Feb · Disclosure
Mr. Ravi Sekhar Kasibhatta, Officer of the company holds Nil shares of Lupin Limited as on date of joining i.e. on February 07, 20077 Feb · Business
Press release dated February 07, 2007, titled "Lupin receives US FDA approval for Sertraline". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Feb · Disclosure
Mr. Puspen Dasgupta, Officer of the company holds 420 shares of Lupin Limited as on date of joining i.e. on February 01, 2007
Jan 2007
31 Jan · Disclosure
Mr. Abir Chaudhuri, Officer of the company holds NIL shares of Lupin Limited as on date of joining i.e. on January 29, 200719 Jan · Business
Press release dated January 19,2007, titled "Lupin and Aspen decide not to pursue their MOU". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Jan · Formation of a subsidiary
Board of Directors of the Company at its meeting held on January 17, 2007 has approved the formation of a 100% subsidiary company in Netherlands by making an initial investment of upto Euro 20,000. The said subsidiary would act as a special purpose vehicle for routing overseas investments to be made by the Company.17 Jan · Business
Press release, dated January 17, 2007, titled "Lupin FY 2006-07 Q3 Net Profit up by 27% at Rs. 560 mn." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Jan · Board meeting
Inter alia, to consider and take on record the Unaudited financial results for the third quarter covering the period October 1, 2006 to December 31, 2006.2 Jan · Business
Press release dated January 02,2007, titled "Lupin gets tentative US FDA approval for Sertraline". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.